Baicalein reduces E46K α-synuclein aggregation in vitro and protects cells against E46K α-synuclein toxicity in cell models of familiar Parkinsonism

Journal of Neurochemistry

Volumn 114, Issue 2, 2010, Pages 419-429

  Jiang, Mali ^a   Porat Shliom, Yair ^a   Pei, Zhong ^a   Cheng, Yong ^a   Xiang, Lan ^a   Sommers, Katherine ^a   Li, Qing ^a   Gillardon, Frank ^b   Hengerer, Bastian ^b   Berlinicke, Cynthia ^a   Smith, Wanli W ^a   Zack, Donald J ^a   Poirier, Michelle A ^a   Ross, Christopher A ^a   Duan, Wenzhen ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

Author keywords

synuclein; aggregation; baicalein; mitochondria depolarization; Parkinson's disease; proteasome inhibition

Indexed keywords

ALPHA SYNUCLEIN; BAICALEIN; E46K PROTEIN; OLIGOMER; PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; ATTENUATION; BETA SHEET; CELL DIFFERENTIATION; CELL PROTECTION; CELL STRAIN; CIRCULAR DICHROISM; CYTOTOXICITY; DEPOLARIZATION; DISORDERS OF MITOCHONDRIAL FUNCTIONS; ELECTRON MICROSCOPY; GENETIC TRANSFECTION; IN VITRO STUDY; MOUSE; NERVE CELL; NONHUMAN; PARKINSON DISEASE; PARKINSONISM; POINT MUTATION; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN EXPRESSION; WILD TYPE;

ALPHA-SYNUCLEIN; ANIMALS; CELL DEATH; CELL DIFFERENTIATION; FLAVANONES; MEMBRANE POTENTIAL, MITOCHONDRIAL; MUTATION; NEURONS; PARKINSONIAN DISORDERS; PC12 CELLS; PROTEASOME ENDOPEPTIDASE COMPLEX; RATS;

EID: 77953853289     PISSN: 00223042     EISSN: 14714159     Source Type: Journal    
DOI: 10.1111/j.1471-4159.2010.06752.x     Document Type: Article

References (59)

1. Baba M., Nakajo S., Tu P. H., Tomita T., Nakaya K., Lee V. M., Trojanowski J. Q. Iwatsubo T. (1998) Aggregation of alpha-synuclein in Lewy bodies of sporadic Parkinson's disease and dementia with Lewy bodies. Am. J. Pathol. 152, 879 884. (Pubitemid 28173348)
2. Betarbet R., Canet-Aviles R. M., Sherer T. B. et al. (2006) Intersecting pathways to neurodegeneration in Parkinson's disease: effects of the pesticide rotenone on DJ-1, alpha-synuclein, and the ubiquitin-proteasome system. Neurobiol. Dis. 22, 404 420.
3. 2+ accelerated aggregation/fibrillation of carboxymethylated bovine 1SS-alpha-lactalbumin. Arch. Biochem. Biophys. 453, 75 86.
4. Brice A. (2006) What can we learn from genes responsible for familial forms of Parkinson's disease?. Bull. Acad. Natl Med. 190 : 485 496 discussion 497-488.
5. Cheng Y., He G., Mu X., Zhang T., Li X., Hu J., Xu B. Du G. (2008) Neuroprotective effect of baicalein against MPTP neurotoxicity: behavioral, biochemical and immunohistochemical profile. Neurosci. Lett. 441, 16 20.
6. Chinta S. J. Andersen J. K. (2005) Dopaminergic neurons. Int. J. Biochem. Cell Biol. 37, 942 946.
7. Choi W., Zibaee S., Jakes R., Serpell L. C., Davletov B., Crowther R. A. Goedert M. (2004) Mutation E46K increases phospholipid binding and assembly into filaments of human alpha-synuclein. FEBS Lett. 576, 363 368.
8. Clayton D. F. George J. M. (1998) The synucleins: a family of proteins involved in synaptic function, plasticity, neurodegeneration and disease. Trends Neurosci. 21, 249 254.
9. Clayton D. F. George J. M. (1999) Synucleins in synaptic plasticity and neurodegenerative disorders. J. Neurosci. Res. 58, 120 129.
10. Corti O. Brice A. (2003) Parkinson's disease: what have we learned from the genes responsible for familial forms?. Med. Sci. (Paris) 19, 613 619.
11. El-Agnaf O. M., Jakes R., Curran M. D. Wallace A. (1998) Effects of the mutations Ala30 to Pro and Ala53 to Thr on the physical and morphological properties of alpha-synuclein protein implicated in Parkinson's disease. FEBS Lett. 440 : 67 70.
12. Elkon H., Don J., Melamed E., Ziv I., Shirvan A. Offen D. (2002) Mutant and wild-type alpha-synuclein interact with mitochondrial cytochrome C oxidase. J. Mol. Neurosci. 18, 229 238.
13. Emmanouilidou E., Stefanis L. Vekrellis K. (2010) Cell-produced alpha-synuclein oligomers are targeted to, and impair, the 26S proteasome. Neurobiol. Aging 31, 953 968.
14. Eriksen J. L., Dawson T. M., Dickson D. W. Petrucelli L. (2003) Caught in the act: alpha-synuclein is the culprit in Parkinson's disease. Neuron 40, 453 456.
15. Fahn S. (2003) Description of Parkinson's disease as a clinical syndrome. Ann. N Y Acad. Sci. 991, 1 14.
16. Fink A. L. (2006) The aggregation and fibrillation of alpha-synuclein. Acc. Chem. Res. 39, 628 634.
17. Fredenburg R. A., Rospigliosi C., Meray R. K., Kessler J. C., Lashuel H. A., Eliezer D. Lansbury P. T., Jr. (2007) The impact of the E46K mutation on the properties of alpha-synuclein in its monomeric and oligomeric states. Biochemistry 46, 7107 7118.
18. Greenbaum E. A., Graves C. L., Mishizen-Eberz A. J., Lupoli M. A., Lynch D. R., Englander S. W., Axelsen P. H. Giasson B. I. (2005) The E46K mutation in alpha-synuclein increases amyloid fibril formation. J. Biol. Chem. 280, 7800 7807.
19. Hong D. P., Fink A. L. Uversky V. N. (2008) Structural characteristics of alpha-synuclein oligomers stabilized by the flavonoid baicalein. J. Mol. Biol. 383, 214 223.
20. Hsu L. J., Sagara Y., Arroyo A., Rockenstein E., Sisk A., Mallory M., Wong J., Takenouchi T., Hashimoto M. Masliah E. (2000) alpha-synuclein promotes mitochondrial deficit and oxidative stress. Am. J. Pathol. 157, 401 410.
21. Im H. I., Joo W. S., Nam E., Lee E. S., Hwang Y. J. Kim Y. S. (2005) Baicalein prevents 6-hydroxydopamine-induced dopaminergic dysfunction and lipid peroxidation in mice. J. Pharmacol. Sci. 98, 185 189.
22. Irvine G. B., El-Agnaf O. M., Shankar G. M. Walsh D. M. (2008) Protein aggregation in the brain: the molecular basis for Alzheimer's and Parkinson's diseases. Mol. Med. 14, 451 464.
23. Jankovic J. (2008) Parkinson's disease: clinical features and diagnosis. J. Neurol. Neurosurg. Psychiatry 79, 368 376.
24. Kazantsev A. G. Kolchinsky A. M. (2008) Central role of alpha-synuclein oligomers in neurodegeneration in Parkinson disease. Arch. Neurol. 65, 1577 1581.
25. Keller J. N., Huang F. F., Dimayuga E. R. Maragos W. F. (2000) Dopamine induces proteasome inhibition in neural PC12 cell line. Free Radic. Biol. Med. 29, 1037 1042.
26. Kostka M., Hogen T., Danzer K. M. et al. (2008) Single particle characterization of iron-induced pore-forming alpha-synuclein oligomers. J. Biol. Chem. 283, 10992 11003.
27. Kragh C. L., Lund L. B., Febbraro F., Hansen H. D., Gai W. P., El-Agnaf O., Richter-Landsberg C. Jensen P. H. (2009) alpha-Synuclein aggregation and Ser-129 phosphorylation-dependent cell death in oligodendroglial cells. J. Biol. Chem. 284, 10211 10222.
28. Kruger R., Kuhn W., Muller T., Woitalla D., Graeber M., Kosel S., Przuntek H., Epplen J. T., Schols L. Riess O. (1998) Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. Nat. Genet. 18, 106 108.
29. Lapchak P. A., Maher P., Schubert D. Zivin J. A. (2007) Baicalein, an antioxidant 12/15-lipoxygenase inhibitor improves clinical rating scores following multiple infarct embolic strokes. Neuroscience 150, 585 591.
30. Lashuel H. A., Hartley D., Petre B. M., Walz T. Lansbury Jr. P. T. (2002a) Neurodegenerative disease: amyloid pores from pathogenic mutations. Nature 418, 291.
31. Lashuel H. A., Petre B. M., Wall J., Simon M., Nowak R. J., Walz T. Lansbury Jr. P. T. (2002b) Alpha-synuclein, especially the Parkinson's disease-associated mutants, forms pore-like annular and tubular protofibrils. J. Mol. Biol. 322, 1089 1102.
32. Lee H. J., Noh Y. H., Lee D. Y., Kim Y. S., Kim K. Y., Chung Y. H., Lee W. B. Kim S. S. (2005) Baicalein attenuates 6-hydroxydopamine-induced neurotoxicity in SH-SY5Y cells. Eur. J. Cell Biol. 84, 897 905.
33. Lee J. H., Lee I. H., Choe Y. J., Kang S., Kim H. Y., Gai W. P., Hahn J. S. Paik S. R. (2009) Real-time analysis of amyloid fibril formation of alpha-synuclein using a fibrillation-state-specific fluorescent probe of JC-1. Biochem. J. 418, 311 323.
34. Luk K. C., Hyde E. G., Trojanowski J. Q. Lee V. M. (2007) Sensitive fluorescence polarization technique for rapid screening of alpha-synuclein oligomerization/fibrillization inhibitors. Biochemistry 46, 12522 12529.
35. Meng X., Munishkina L. A., Fink A. L. Uversky V. N. (2009) Molecular mechanisms underlying the flavonoid-induced inhibition of alpha-synuclein fibrillation. Biochemistry 48, 8206 8224.
36. Moussa C. E., Mahmoodian F., Tomita Y. Sidhu A. (2008) Dopamine differentially induces aggregation of A53T mutant and wild type alpha-synuclein: insights into the protein chemistry of Parkinson's disease. Biochem. Biophys. Res. Commun. 365, 833 839.
37. Mu X., He G., Cheng Y., Li X., Xu B. Du G. (2009) Baicalein exerts neuroprotective effects in 6-hydroxydopamine-induced experimental parkinsonism in vivo and in vitro. Pharmacol. Biochem. Behav. 92, 642 648.
38. Ono K., Hirohata M. Yamada M. (2008) Alpha-synuclein assembly as a therapeutic target of Parkinson's disease and related disorders. Curr. Pharm. Des. 14, 3247 3266.
39. Pandey N., Schmidt R. E. Galvin J. E. (2006) The alpha-synuclein mutation E46K promotes aggregation in cultured cells. Exp. Neurol. 197, 515 520.
40. Papapetropoulos S., Ellul J., Paschalis C., Athanassiadou A., Papadimitriou A. Papapetropoulos T. (2003) Clinical characteristics of the alpha-synuclein mutation (G209A)-associated Parkinson's disease in comparison with other forms of familial Parkinson's disease in Greece. Eur. J. Neurol. 10, 281 286.
41. Polymeropoulos M. H., Lavedan C., Leroy E. et al. (1997) Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 276, 2045 2047.
42. Ross C. A. Poirier M. A. (2004) Protein aggregation and neurodegenerative disease. Nat. Med. 10 (Suppl S10 S17.
43. Shieh D. E., Liu L. T. Lin C. C. (2000) Antioxidant and free radical scavenging effects of baicalein, baicalin and wogonin. Anticancer Res. 20, 2861 2865.
44. Singleton A. B. (2005) Altered alpha-synuclein homeostasis causing Parkinson's disease: the potential roles of dardarin. Trends Neurosci. 28, 416 421.
45. Singleton A. B., Farrer M., Johnson J. et al. (2003) alpha-Synuclein locus triplication causes Parkinson's disease. Science 302, 841.
46. Smith W. W., Jiang H., Pei Z., Tanaka Y., Morita H., Sawa A., Dawson V. L., Dawson T. M. Ross C. A. (2005) Endoplasmic reticulum stress and mitochondrial cell death pathways mediate A53T mutant alpha-synuclein-induced toxicity. Hum. Mol. Genet. 14, 3801 3811.
47. Spillantini M. G., Schmidt M. L., Lee V. M., Trojanowski J. Q., Jakes R. Goedert M. (1997) Alpha-synuclein in Lewy bodies. Nature 388, 839 840.
48. Stefanis L., Larsen K. E., Rideout H. J., Sulzer D. Greene L. A. (2001) Expression of A53T mutant but not wild-type alpha-synuclein in PC12 cells induces alterations of the ubiquitin-dependent degradation system, loss of dopamine release, and autophagic cell death. J. Neurosci. 21, 9549 9560.
49. Tanaka Y., Engelender S., Igarashi S., Rao R. K., Wanner T., Tanzi R. E., Sawa A., V L. D., Dawson T. M. Ross C. A. (2001) Inducible expression of mutant alpha-synuclein decreases proteasome activity and increases sensitivity to mitochondria-dependent apoptosis. Hum. Mol. Genet. 10, 919 926.
50. Uversky V. N. (2003) A protein-chameleon: conformational plasticity of alpha-synuclein, a disordered protein involved in neurodegenerative disorders. J. Biomol. Struct. Dyn. 21, 211 234.
51. Uversky V. N. (2008) Alpha-synuclein misfolding and neurodegenerative diseases. Curr. Protein Pept. Sci. 9, 507 540.
52. Wakabayashi K. Takahashi H. (2007) Pathology of familial Parkinson's disease. Brain Nerve 59, 851 864.
53. Wang S. Y., Wang H. H., Chi C. W., Chen C. F. Liao J. F. (2004) Effects of baicalein on beta-amyloid peptide-(25-35)-induced amnesia in mice. Eur. J. Pharmacol. 506, 55 61.
54. Wang W., Duan W., Igarashi S., Morita H., Nakamura M. Ross C. A. (2005) Compounds blocking mutant huntingtin toxicity identified using a Huntington's disease neuronal cell model. Neurobiol. Dis. 20, 500 508.
55. Waxman E. A. Giasson B. I. (2009) Molecular mechanisms of alpha-synuclein neurodegeneration. Biochim. Biophys. Acta 1792, 616 624.
56. Wu P. H., Shen Y. C., Wang Y. H., Chi C. W. Yen J. C. (2006) Baicalein attenuates methamphetamine-induced loss of dopamine transporter in mouse striatum. Toxicology 226, 238 245.
57. Yao Z. Wood N. W. (2009) Cell death pathways in Parkinson's disease: role of mitochondria. Antioxid. Redox Signal. 11, 2135 2149.
58. Zarranz J. J., Alegre J., Gomez-Esteban J. C. et al. (2004) The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia. Ann. Neurol. 55, 164 173.
59. Zhu M., Rajamani S., Kaylor J., Han S., Zhou F. Fink A. L. (2004) The flavonoid baicalein inhibits fibrillation of alpha-synuclein and disaggregates existing fibrils. J. Biol. Chem. 279, 26846 26857. (Pubitemid 38812518)